Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22192238 | 0.95 | MEN1 (0.70) | MEN1KMT2AL3MBTL1PGRNR1H4 | |
| SCHEMBL19619022 | 0.87 | PGR (0.86) | MEN1KMT2APGRNR1H4NPC1 | |
| SCHEMBL22192227 | 0.85 | NR1H4 (0.63) | MEN1KMT2AL3MBTL1PGRNR1H4 | |
| SCHEMBL22192258 | 0.84 | PGR (0.93) | MEN1KMT2APGRNR1H4LMNA | |
| SCHEMBL2467402 | 0.84 | PLAU (0.78) | MEN1KMT2ANR1H4MAPTSMN1; SMN2 | |
| SCHEMBL11030916 | 0.83 | NPC1 (0.64) | MEN1KMT2AL3MBTL1PGRLMNA | |
| SCHEMBL18941328 | 0.83 | NPC1 (0.66) | MEN1KMT2AL3MBTL1PGRNR1H4 | |
| SCHEMBL8361085 | 0.82 | PGR (0.96) | MEN1KMT2APGRNR1H4MAPT | |
| SCHEMBL6408811 | 0.82 | MEN1 (0.64) | MEN1KMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL22192207 | 0.82 | PGR (0.58) | MEN1KMT2AL3MBTL1PGRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| EP-0763523-B1 | NAPHTHALENE DERIVATIVE | TEIJIN LTD (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5945450-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1999-08-31 | — | — | US | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
| EP-0763523-A1 | NAPHTHALENE DERIVATIVE | TEIJIN LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | MEN1 3155/4885KMT2A 553/4885L3MBTL1 2029/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | MEN1 1552/4885KMT2A 799/4885L3MBTL1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.